Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Leustatin

(Cladribine)

ApprovedSmall molecule

Cladribine is used to treat certain types of blood cancers and leukemias, and also to treat multiple sclerosis by helping to suppress the overactive immune system that damages nerve cells.[2] Leustatin is currently approved and in use across 30 indications[4].[1]

Leustatin is one of 638 small molecule programs targeting Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. It is currently in Approved.

30

Indications

95

Total Trials

29

Active Trials

637

Competitors

2

FDA Applications

NDA/BLA/ANDA regulatory filings

3

Patents

Pipeline

Status by Indication[4][1]

Indication

Precursor T-Cell Lymphoblastic Leukemia-LymphomaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Lymphoblastic LymphomaActive, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

Systemic MastocytosisApproved

Central Nervous System NeoplasmApproved

LymphomaActive, not recruiting

Immune System DiseaseActive, not recruiting

HistiocytosisApproved

Hairy Cell LeukemiaActive, not recruiting

Precursor T-Cell Lymphoblastic Leukemia-LymphomaPreclinical

Active, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Lymphoblastic LymphomaApproved

Active, not recruiting

Unspecified Peripheral T-Cell LymphomaApproved

Approved

Systemic MastocytosisApproved

Approved

Central Nervous System NeoplasmApproved

Approved

LymphomaPhase 3

Active, not recruiting

Immune System DiseaseApproved

Active, not recruiting

HistiocytosisApproved

Approved

Hairy Cell LeukemiaPhase 2

Active, not recruiting

Showing 10 of 30 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Leustatin

Zofran

Norvir

Wellcovorin

GGlaxo Dba Glaxosmithkline

Nuvigil

NNuvo Research GmbH

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Stem Cells

KKang Stem Biotech Co., Ltd.

VP-16

FFundamenta Therapeutics, Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalActive, not recruiting

Treatment

NCT04178005

Q1 2027

Phase 1Recruiting

Chronic Myelomonocytic Leukemia

NCT04375631

Q2 2027

Phase 2Recruiting

Acute Myeloid Leukemia

NCT03586609

Phase 2Recruiting

Hairy Cell Leukemia

NCT00412594

Q3 2027

Phase 2Recruiting

Hairy Cell Leukemia

NCT06561360

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia14 trials

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Recruiting·UUniversity of Washington·Phase 1/2·NCT04797767·62 enrolled

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Terminated·UUniversity of Washington·Phase 1·NCT04196010·13 enrolled

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03586609·145 enrolled

Show 11 more trials

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Completed·MMedical College of Wisconsin·Phase 1·NCT03441048·26 enrolled

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1/2·NCT02416908·40 enrolled

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02096055·44 enrolled

Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00003178·120 enrolled

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT04848974·37 enrolled

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Withdrawn·MMedical College of Wisconsin·Phase 1·NCT06007911

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

Completed·UUniversity of Washington·Phase 2·NCT03012672·50 enrolled

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

Unknown status·SSun Yat-sen University·Phase 2·NCT03181815·48 enrolled

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Unknown status·GGe Zheng·Phase 2·NCT05330364·31 enrolled

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT07053020·58 enrolled

Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT04195945·60 enrolled

Multiple Sclerosis9 trials

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

Completed· Merck & Co. logo

Merck & Co.··NCT04934800·256 enrolled

Oral Cladribine in Early Multiple Sclerosis (MS)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT00725985·617 enrolled

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis

Completed·WWashington University School of Medicine·Phase 4·NCT03963375·47 enrolled

Show 6 more trials

Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00938366·18 enrolled

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT00436826·172 enrolled

Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)

Completed·OOslo University Hospital·Phase 3·NCT04121403·267 enrolled

Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients

Unknown status·PPontificia Universidade Católica do Rio Grande do Sul·Phase 4·NCT05902429·10 enrolled

ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Active, not recruiting·QQueen Mary University of London·Phase 2/3·NCT04695080·204 enrolled

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Recruiting·IInstitute of Psychiatry and Neurology, Warsaw·Phase 2/3·NCT05961644·188 enrolled

Myelodysplastic Syndrome6 trials

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04047641·80 enrolled

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·UUniversity of Washington·Phase 1/2·NCT02728050·84 enrolled

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02250937·116 enrolled

Show 3 more trials

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01515527·160 enrolled

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02115295·508 enrolled

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·CChildren's Oncology Group·Phase 2·NCT00002805·115 enrolled

Lymphoma5 trials

Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00053027·30 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Terminated·EEuropean Institute of Oncology·Phase 2·NCT01446900·25 enrolled

Show 2 more trials

Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

Unknown status·SSichuan University·Phase 2·NCT03151876·93 enrolled

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

Unknown status·SSichuan University·Phase 2·NCT03602131·30 enrolled

Mantle Cell Lymphoma4 trials

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Completed·UUniversity of Arizona·Phase 2·NCT00980395·24 enrolled

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT01439750·13 enrolled

Cladribine in Patients With Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002879·51 enrolled

Show 1 more trial

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT00787969·74 enrolled

38 more indications

Hairy Cell Leukemia4 trials

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT06965114·84 enrolled

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00412594·150 enrolled

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06561360·86 enrolled

Show 1 more trial

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00923013·175 enrolled

Chronic Lymphocytic Leukemia3 trials

Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00003174·80 enrolled

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00764517·57 enrolled

A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Completed· Roche logo

Roche·Phase 3·NCT00718549·128 enrolled

Efficacy and Safety2 trials

the Efficacy and Safety of CLAE in R/R T-ALL/LBL

Unknown status·PPeking University Third Hospital··NCT04679506·50 enrolled

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Unknown status·SSun Yat-sen University·Phase 2·NCT04254640·34 enrolled

Myeloid Neoplasm2 trials

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT03531918·66 enrolled

Refractory AML2 trials

CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 3·NCT03384225·120 enrolled

CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 3·NCT03384212·120 enrolled

Relapsed/Refractory AML2 trials

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 4·NCT06763666·172 enrolled

Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML

Completed·WWashington University School of Medicine·Phase 1·NCT01161550·11 enrolled

Chronic Myelomonocytic Leukemia2 trials

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Recruiting·FFred Hutchinson Cancer Center·Phase 1·NCT04375631·120 enrolled

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05365035·60 enrolled

Myelodysplastic Syndromes2 trials

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes

Active, not recruiting·MMaria Sklodowska-Curie National Research Institute of Oncology·Phase 2·NCT04861207·40 enrolled

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT02044796·199 enrolled

Acute Lymphoblastic Leukemia2 trials

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed·GGoethe University·Phase 4·NCT00198991·1,883 enrolled

Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia

Unknown status·SSun Yat-sen University·Phase 2·NCT03318419·50 enrolled

Treatment2 trials

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT04178005·40 enrolled

Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05578378·32 enrolled

AML2 trials

Cladribine Venetoclax in Monocytic AML

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06232655·20 enrolled

Epacadostat, Cladribine and Cytarabine (ECC) in AML

Withdrawn·IInsel Gruppe AG, University Hospital Bern·Phase 1·NCT03491579

Newly Diagnosed2 trials

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT02921061·28 enrolled

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT06504459·40 enrolled

Chronic Myelogenous Leukemia2 trials

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00002833·53 enrolled

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Completed·UUniversity of Rochester·Phase 1·NCT00258271·18 enrolled

Relapsed or Refractory2 trials

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07032727·68 enrolled

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Recruiting·SStanford University·Phase 1/2·NCT06561152·20 enrolled

Acute Monocytic Leukemia1 trial

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT05313958·43 enrolled

MDS1 trial

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.··NCT03933215·100 enrolled

Stem Cell Transplantation1 trial

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·NNorthwestern University·Phase 1·NCT00004904

Acute Leukemia1 trial

A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT06474663

Relapsed/Refractory1 trial

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Withdrawn·AAyman H Qasrawi·Phase 1·NCT05330377

Leukemia1 trial

Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)

Unknown status·UUniversity Hospital, Bonn·Phase 2·NCT00126321·50 enrolled

T-Cell Prolymphocytic Leukemia1 trial

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT07311746·36 enrolled

Elderly Patients1 trial

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Unknown status·LLanZhou University·N/A·NCT05053425·30 enrolled

Malignant Glioma1 trial

Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00019071

Lymphoblastic Lymphoma1 trial

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199017·75 enrolled

Intravenous1 trial

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06021600·40 enrolled

Sclerosing Cholangitis1 trial

Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004762·5 enrolled

Effects of Chemotherapy1 trial

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03589729·100 enrolled

Induction Therapy1 trial

Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL

Completed·SSwiss Cancer Institute·Phase 2·NCT00072007·43 enrolled

T-cell acute lymphoblastic leukemia1 trial

Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath

Completed·GGoethe University·Phase 2·NCT00199030·8 enrolled

Outcome1 trial

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Recruiting·MM.D. Anderson Cancer Center·Phase 2/3·NCT04708054·324 enrolled

Frontline1 trial

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Withdrawn·UUniversity of Florida·Phase 2·NCT05766514

Prospective1 trial

A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets

Unknown status·—·Phase 4·NCT04550455·30 enrolled

Oral1 trial

Relationship Between Oral DMT Burden and Adherence in MS

Enrolling by invitation·MMonash University··NCT04676204·323 enrolled

Langerhans Cell Histiocytosis1 trial

Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01473797·10 enrolled

Trial1 trial

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Terminated·DDelta-Fly Pharma, Inc.·Phase 3·NCT03926624·167 enrolled

Infusion1 trial

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.··NCT03933202·291 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

Unknown status·CClaudio Gobbi··NCT04640818·45 enrolled

Unspecified3 trials

Effects of Cladribine Tablets on the PK of Microgynon®

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03745144·28 enrolled

CLARITY Extension Study

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT00641537·867 enrolled

Cladribine Tablets as an Exit Therapy Strategy

Not yet recruiting·UUniversity Hospital, Strasbourg, France··NCT06887426·450 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 26, 1993

LEUSTATIN

NDA NDA020229

Mar 29, 2019

MAVENCLAD

NDA NDA022561

Sources

References

[1]
ClinicalTrials.gov — 95 trial records for Cladribine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Leustatin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Cladribine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Cladribine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022561). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Leustatin. U.S. Food & Drug Administration.
[7]
SEC EDGAR — EMD Serono company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: EMD Serono

Patent Landscape[6]

Patent Cliff

Nov 23, 2038

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10849919Nov 23, 2038

12533408Sep 10, 2041

12539329Sep 10, 2041

Related News